Sequential afatinib and osimertinib in patients with EGFR mutation-positive NSCLC and acquired T790M: A global non-interventional study (UpSwinG) - ScienceDirect
Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset - ScienceDirect
肺癌のFLAURA試験のOSの結果発表、治療シークエンスの議論が深まる(2ページ目)：日経メディカル
FLAURA-Studie zum fortgeschrittenen EGFRm NSCLC: Osimertinib kann Gesamtüberleben verlängern
First-line osimertinib in elderly patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer: a retrospective multicenter study (HOT2002) | Scientific Reports
Efficacy of Metastatic NSCLC – TAGRISSO® (osimertinib) Nurse Center
PFS (A) and OS (B) in osimertinib and gefitinib treatment groups. *For... | Download Scientific Diagram
Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer | NEJM
Turning EGFR mutation-positive non-small-cell lung cancer into a chronic disease: optimal sequential therapy with EGFR tyrosine kinase inhibitors - Vera Hirsh, 2018
Osimertinib versus Standard of Care EGFR TKI as First‐Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset | Semantic Scholar
EGFR-mutant lung cancer: sequencing as a major topic in light of new data - memoinOncology
Efficacy of TAGRISSO® (osimertinib) in Metastatic EGFRm NSCLC
PD-L1 strong expressions affect the clinical outcomes of osimertinib in treatment naïve advanced EGFR-mutant non-small cell lung cancer patients | Scientific Reports
First-line osimertinib in elderly patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer: a retrospective multicenter study (HOT2002) | Scientific Reports
FLAURA Trial: Survival Benefit Confirmed for Tyrosine Kinase Inhibitor in EGFR Mutation-Positive Advanced NSCLC - The Medical Xchange
Actionable Alterations - NSCLC Treatment Paradigm - Text Module - NSCLC Practical Guidance - Oncology - Clinical Care Options
Results for two new third-generation EGFR TKIs
Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis - Annals of Oncology
Practical Strategies to Guideline-Recommended Biomarker Testing in NSCLC. - ppt download
大分での肺がん診療:FLAURA日本人サブグループ解析
Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study | SpringerLink
New England Journal of Medicine publishes results of Phase III FLAURA trial in the 1st-line treatment of EGFR-mutated non-small cell lung cancer
Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset - Journal of Thoracic Oncology
Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study | SpringerLink
